Pacific Bio (NASDAQ: PACB) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $25.1 million versus the consensus estimate of $24.68 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.